Admedus receives first U.S. orders

THE ROADHOUSE PHARMACY: Admedus (ASX: AHZ) has received the first sales orders for the company’s CardioCel® product in the US market.

The company said the initial US sales orders have come ahead of its expected mid-year timing.
“This is an important milestone for the company as we look to grow our revenue over the coming twelve months and beyond,” Admedus chief executive officer Lee Rodne said in the company’s announcement to the Australian Securities Exchange.

“We are aiming for CardioCel® to be in use in 15 key centres in Europe and the US over the next 12 months, which will provide us with a significant presence in the market.”

The first sales orders for CardioCel® in the US market follow a presentation by Admedus to US cardio-thoracic surgeons during the recent American Association of Thoracic Surgeons (AATS) conference in Toronto.

In Europe, Admedus officially launched CardioCel® late in 2013, with the aim of introducing it into 15 key cardio-thoracic centres.

To date, CardioCel® has been used in eight of the target centres in Europe and the company indicated it expects several more to come on stream by mid-year.

Admedus claims surgeons who have used CardioCel® in surgical procedures have not reported any issues.

CardioCel® continues to be used in Australia under the Authorised Prescriber Scheme with over 100 patients implanted.

Email: info@admedus.com.au

Website: www.admedus.com